Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 6;11(11):957. doi: 10.1038/s41419-020-03151-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — Bar-charts showing HT, days (A), ESR, mm/h (B) and antithrombin III, % (C) in younger (<60, light gray) or older (>60, dark gray) COVID-19 patients. Bar-charts showing T lymphocyte percentage (CD3⁺ T cells) in healthy (red), age-matched controls and COVID-19 patients (gray) (D), or in younger (<60, light gray) or older (>60, dark gray) COVID-19 patients (E). FACS analysis of immune cell subsets in younger (<60) and older (>60) COVID-19 patients. Bar-charts showing the Percentage of total CD8⁺ (F) or CD4⁺ (G) lymphocytes and the expression of TIM3, ICOS, and PD1 in younger (<60, light gray) or older (>60, dark gray) (H–I) COVID-19 patients; the percentage of NK and NKT cells in healthy age-matched controls and COVID-19 patients (L); the percentage of NKT and NK cells in younger (<60) and older (>60) COVID-19 patients (M); NKG2A expression in NK cells in healthy age-matched controls or COVID-19 patients (N) and in younger (<60) or older (>60) COVID-19 patients (O); the percentage of CD11b⁺ myeloid cells in healthy age-matched controls and COVID-19 patients (P) and in younger (<60) or older (>60) COVID19 patients (Q); the percentage of classical CD11b⁺CD14^highCD16⁻ (R), and non-classical CD11b⁺CD14^l^owCD16⁺ (S) monocytes, and LD-PMN CD11b⁺HLA-DR^lownegCD14⁻CD15⁺CD66b⁺ (T) in younger (<60) or older (>60) COVID-19 patients. Data are represented as mean of the percentage of parent population ± SEM. Gating strategy in Fig S6. Mann-Whitney test; *p < 0.05, **p < 0.01, ****p < 0.0001. Healthy N = 11, COVID-19 Patients = 10 (<60 N = 5, >60 N = 5).